GNI Scientists Complete Three Grant Projects for Drug Target Discovery in China

Tokyo, March 18, 2008 – GNI Ltd., a leading biopharmaceutical company in China and Japan, announced today that scientists at its China based affiliate Shanghai Genomics, Inc. have completed three grant projects from the Shanghai government. The grants were used to support drug target discovery research and development of an anti-fibrosis therapeutic agent in Shanghai Genomics. The titles of the grants are: 1) Development of novel drug target RX53 and related drugs; 2) Development of novel anti-liver-fibrosis drug; and 3) Discovery and identification of target genes with drug development potentials. All three grant projects started in 2005. Results of these projects were examined and accepted by scientific review committees composed of leading scientists in Shanghai.

Government in the Shanghai Metropolitan Area has set up foundations to support hi-tech development projects. Life science is one of the major focus areas for grant support. In the past 5 years, Shanghai Genomics has received multiple grants from both national and local science foundations. These grants provide Shanghai Genomics important financial resources to build an integrated drug discovery platform in Shanghai. Grant projects also provided opportunities for collaboration between the company and universities around the country. Moreover, research results from these grants have led to multiple publications and patents for Shanghai Genomics.

“These grants indicate that the environment in Shanghai is very friendly to the growth of the biotech industry,” said Dr. Ying Luo, Chief Executive Officer of Shanghai Genomics and GNI. “Development of new drugs for patients in Asia has always been our mission since the founding days of GNI and Shanghai Genomics. This effort will continue after completion of the grant projects.”

For further inquiries

Mayumi Higuchi Tel: +81 (03) 3580-0751
Email: infojapan@gene-networks.com
Ying Luo Tel: +86 1381-769-8961
Email: bd@shanghaigenomics.com

About GNI

Founded in 2001, GNI, Ltd. is a clinical-stage international drug development company with its headquarters in Tokyo, Japan, and major operations in Shanghai, China. In June 2005, GNI acquired Shanghai Genomics, which was also founded in 2001, and currently operates an integrated drug discovery and development platform in Shanghai. The combined strengths of GNI and Shanghai Genomics have resulted in research collaborations with major international pharmaceutical companies. GNI has offices in Beijing, Tianjin, and Zhengzhou, China and Fukuoka, Japan. For further information, please visit www.gnipharma.com and www.shanghaigenomics.com.

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "could," "may," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. GNI does not undertake any obligation to update forward-looking statements.